Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Problems of variable biomarker evaluation in stratified medicine research--A case study of ERCC1 in non-small-cell lung cancer.

Malottki K, Popat S, Deeks JJ, Riley RD, Nicholson AG, Billingham L.

Lung Cancer. 2016 Feb;92:1-7. doi: 10.1016/j.lungcan.2015.11.017. Epub 2015 Nov 26. Review.

2.

Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).

Lee SM, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, Middleton G, Ahmed S, Hicks J, Crosse B, Napier M, Singer JM, Ferry D, Lewanski C, Forster M, Rolls SA, Capitanio A, Rudd R, Iles N, Ngai Y, Gandy M, Lillywhite R, Hackshaw A.

J Clin Oncol. 2017 Feb;35(4):402-411. doi: 10.1200/JCO.2016.68.1841. Epub 2016 Nov 28.

PMID:
27893326
3.
4.

Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR.

J Clin Oncol. 2013 Jul 1;31(19):2404-12. doi: 10.1200/JCO.2012.46.9783. Epub 2013 May 20.

5.

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.

Vilmar A, Sørensen JB.

Lung Cancer. 2009 May;64(2):131-9. doi: 10.1016/j.lungcan.2008.08.006. Epub 2008 Sep 19. Review.

PMID:
18804893
6.

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC.

N Engl J Med. 2013 Mar 21;368(12):1101-10. doi: 10.1056/NEJMoa1214271.

7.

Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).

Kotoula V, Krikelis D, Karavasilis V, Koletsa T, Eleftheraki AG, Televantou D, Christodoulou C, Dimoudis S, Korantzis I, Pectasides D, Syrigos KN, Kosmidis PA, Fountzilas G.

BMC Cancer. 2012 Aug 6;12:342. doi: 10.1186/1471-2407-12-342.

8.

Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.

Podmaniczky E, Fábián K, Pápay J, Puskás R, Gyulai M, Furák J, Tiszlavicz L, Losonczy G, Tímár J, Moldvay J.

Pathol Oncol Res. 2015 Apr;21(2):423-31. doi: 10.1007/s12253-014-9839-x. Epub 2014 Sep 7.

PMID:
25194563
10.

[Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].

Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.

Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):33-7. Chinese.

PMID:
19538866
11.

Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.

Muley TR, Sianidou M, Thomas M, Bischoff H, Dienemann H, Meister M, Schneider MA, Schnabel PA, Warth A.

Anticancer Res. 2014 Jul;34(7):3707-13.

PMID:
24982391
12.
13.

Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.

Krawczyk P, Wojas-Krawczyk K, Mlak R, Kucharczyk T, Biernacka B, Milanowski J.

Folia Histochem Cytobiol. 2012 Apr 24;50(1):80-6. doi: 10.2478/18700.

14.

ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.

Han JY, Lee GK, Lim KY, Lee YJ, Nam BH, Lee JS.

Cancer Res Treat. 2017 Jul;49(3):678-687. doi: 10.4143/crt.2016.365. Epub 2016 Oct 11.

15.

Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.

Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y, Wang D.

Cancer Chemother Pharmacol. 2014 Oct;74(4):777-86. doi: 10.1007/s00280-014-2562-1. Epub 2014 Aug 9.

PMID:
25107571
16.

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

Joerger M, deJong D, Burylo A, Burgers JA, Baas P, Huitema AD, Beijnen JH, Schellens JH.

Lung Cancer. 2011 Nov;74(2):310-7. doi: 10.1016/j.lungcan.2011.03.016. Epub 2011 Apr 29.

PMID:
21529986
17.

Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.

Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F.

Lung Cancer. 2013 Nov;82(2):288-93. doi: 10.1016/j.lungcan.2013.08.018. Epub 2013 Sep 3.

PMID:
24045016
18.

ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Kalikaki A, Voutsina A, Koutsopoulos A, Papadaki C, Sfakianaki M, Yachnakis E, Xyrafas A, Kotsakis A, Agelaki S, Souglakos J, Mavroudis D, Georgoulias V.

Cancer Invest. 2015 Apr;33(4):107-13. doi: 10.3109/07357907.2014.1001897. Epub 2015 Feb 3.

PMID:
25647444
19.

Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.

Schneider JG, Farhadfar N, Sivapiragasam A, Geller M, Islam S, Selbs E.

Oncologist. 2014 May;19(5):459-65. doi: 10.1634/theoncologist.2013-0311. Epub 2014 Apr 4.

20.

Automated ERCC1 immunohistochemistry in non-small cell lung cancer: comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297.

Arbogast S, Behnke S, Opitz I, Stahel RA, Seifert B, Weder W, Moch H, Soltermann A.

Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):99-105. doi: 10.1097/PAI.0b013e3181f1feeb.

PMID:
21030862

Supplemental Content

Support Center